Discover
IOVA
Iovance Biotherapeutics, Inc.
3.97
1 x 3.37
1 x 4.55
bid
ask
-
0.19
4.57%
1 @ 04:00 PM
4.00 +0.03 (0.76%)
| Ytd | 45.42% | |
| 1y | 128.16% |
3.85
day range
4.29
1.68
52 week range
5.63
| Open | 4.16 | Prev Close | 4.16 | Low | 3.85 | High | 4.29 | Mkt Cap | 1.77B |
| Vol | 21.22M | Avg Vol | 14.84M | EPS | -0.92 | P/E | N/A | Forward P/E | -12.44 |
| Beta | 0.70 | Short Ratio | 8.09 | Inst. Own | 67.51% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 3.85 | 200-d Avg | 3.04 | 1yr Est | 8.80 |
IOVA News
benzinga.com
Iovance Biotherapeutics Files Prospectus For Offering Mixed Shelf; Terms Undisclosed
https://www.sec.gov/Archives/edgar/data/1425205/000110465926075778/iova-20260618xs3asr.htm
benzinga.com
Iovance Biotherapeutics Says Therapeutic Goods Administration Of Australia Grants Approval With Cond
First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for a
benzinga.com
Iovance Biotherapeutics Announces Allowance To Proceed From FDA For Investigational New Drug Applica
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovati